Obesity Management: Pharmacotherapy

Area of Science:

• Pharmacology
• Endocrinology
• Public Health

Background:

• Obesity is a complex condition requiring multifaceted treatment approaches.
• Pharmacotherapy is an essential component of comprehensive obesity management.
• Current FDA-approved anti-obesity drugs include centrally acting agents, lipase inhibitors, and incretin mimetics.

Purpose of the Study:

• To review the role of anti-obesity medications in managing overweight and obesity.
• To highlight the efficacy of newer agents, particularly incretin mimetics.
• To discuss considerations for drug selection and persistent barriers to access.

Main Methods:

• Literature review of current anti-obesity pharmacotherapies.
• Analysis of clinical trial data for weight loss efficacy.
• Discussion of individualized treatment strategies and access challenges.

Main Results:

• Incretin mimetics, such as GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 RAs (tirzepatide), offer substantial weight loss, with tirzepatide achieving >20% reduction in some cases.
• Anti-obesity drugs are recommended as initial or first-line treatment for adults with overweight/obesity, particularly those with comorbidities or at high risk.
• Individualized drug selection based on comorbidities, cost, and patient preference is crucial.

Conclusions:

• Pharmacotherapy is a vital tool for obesity treatment, with incretin mimetics demonstrating significant efficacy.
• Addressing barriers such as prescriber hesitancy, high costs, and limited insurance coverage is essential for improving patient access and outcomes.
• Continued innovation and expanded education are critical for advancing obesity pharmacotherapy.